RT Journal Article
SR Electronic
T1 Emergence and antibody evasion of BQ and BA.2.75 SARS-CoV-2 sublineages in the face of maturing antibody breadth at the population level
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.06.22283000
DO 10.1101/2022.12.06.22283000
A1 Akerman, Anouschka
A1 Milogiannakis, Vanessa
A1 Jean, Tyra
A1 Esneu, Camille
A1 Silva, Mariana Ruiz
A1 Ison, Timothy
A1 Fitcher, Christina
A1 Lopez, Joseph A
A1 Chandra, Deborah
A1 Naing, Zin
A1 Caguicla, Joanna
A1 Li, Daiyang
A1 Walker, Gregory
A1 Amatayakul-Chantler, Supavadee
A1 Roth, Nathan
A1 Manni, Sandro
A1 Hauser, Thomas
A1 Barnes, Thomas
A1 Condylios, Anna
A1 Yeang, Malinna
A1 Wong, Maureen
A1 Foster, Charles S.P.
A1 Lee, Sharon
A1 Song, Yang
A1 Mao, Lijun
A1 Sigmund, Allison
A1 Phu, Amy
A1 Vande More, Ann Marie
A1 Hunt, Stephanie
A1 Douglas, Mark
A1 Caterson, Ian
A1 Sandgren, Kerrie
A1 Bull, Rowena
A1 Lloyd, Andrew
A1 Triccas, Jamie
A1 Tangye, Stuart
A1 Bartlett, Nathan W
A1 Darley, David
A1 Matthews, Gail
A1 Stark, Damien J.
A1 Rawlinson, William D.
A1 Brilot, Fabienne
A1 Cunningham, Anthony L
A1 Kelleher, Anthony D.
A1 Aggarwal, Anupriya
A1 Turville, Stuart G.
YR 2022
UL http://medrxiv.org/content/early/2022/12/21/2022.12.06.22283000.abstract
AB The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and related sub-lineages. Over the course of 2022, we monitored the potency and breadth of antibody neutralization responses to many emerging variants at two levels: (i) we tracked over 400,000 U.S. plasma donors over time through various vaccine booster roll outs and Omicron waves using sequentially collected IgG pools; (ii) we mapped the antibody response in individuals using blood from strigently curated vaccine and convalescent cohorts. In pooled IgG samples, we observed the maturation of neutralization breadth to Omicron variants over time through continuing vaccine and infection waves. Importantly, in many cases we observed increased antibody breadth to variants that were yet to be in circulation. Determination of viral neutralization at the cohort level supported equivalent coverage across prior and emerging variants with emerging isolates BQ.1.1, XBB.1, BR.2.1 and XBF the most evasive. Further, these emerging variants were resistant to Evusheld, whilst neutralization resistance to Sotrovimab was restricted to BQ.1.1 and XBF. We conclude at this current point in time that dominant variants derived from BQ and BA.2.75 lineages can evade antibodies at levels equivalent to their most evasive lineage counterparts but sustain an entry phenotype that continues to promote an additional outgrowth advantage. In Australia, BR2.1 and XBF share this phenotype and are dominating across NSW and Victoria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily supported by Australian Medical Foundation research grants MRF2005760 (ST, GM & WDR), MRF2001684 (ADK and ST) and Medical Research Future Fund Antiviral Development Call grant (WDR), Medical Research Future Fund COVID-19 grant (MRFF2001684, ADK & SGT) and the New South Wales Health COVID-19 Research Grants Round 2 (SGT) and the NSW Vaccine Infection and immunology Collaborative (VIIM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human serum samples were obtained with written informed consent from the participants and have been approved under Ethics review at St Vincents Hospital, Darlinghurst Sydney Australia (ADAPT Cohort) and Ethics review at the Western Sydney Local Health (WSLHD) District (VIIM cohort)(2020/ETH00964; 2020/ETH02068; 2019/ETH03336; 2021/ETH00180; 2021/ETH0042). All primary isolates used herein were obtained from de-identified remnant diagnostic swabs that had completed all diagnostic testing under approval by the New South Wales Chief Health Officer following independent scientific review and as outlined in the ADAPT ethics protocol 2020/ETH00964.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data for generating the figures are available in the online version of the paper in the supplmentary tables. Any other data are available on request